C-DOCTOR Interdisciplinary Translational Project Team, Hydronovo, received a $2.3 million California Institute for Regenerative Medicine (CIRM) Translational Stage research grant to fund the development of their small molecule therapy and related translational activities. This funding, leveraged in addition to the funding and support for proof-of-concept studies provided by C-DOCTOR and the National Institutes of Health/National Institute of Dental and Craniofacial Research, will enable their goal of completing pivotal preclinical studies ahead of IND filing with the FDA. The Hydronovo team takes a monumental step towards clinical trials with their outstanding accomplishment in receiving this grant.
Hydronovo was co-founded by UCSF's Sarah Knox, PhD and CSO, and Chelsea Bahney, PhD and CEO/COO. The company focuses on using an injectable neuromimetic hydrogel to drive tissue regeneration.